Cost benefit analysis and the FDA: measuring the costs and benefits of drug approval under the PDUFA I-II, 1998–2005
Crossref DOI link: https://doi.org/10.1007/s11149-024-09477-2
Published Online: 2024-04-19
Update policy: https://doi.org/10.1007/springer_crossmark_policy
DeCanio, Samuel http://orcid.org/0000-0002-4722-9326
Text and Data Mining valid from 2024-04-19
Version of Record valid from 2024-04-19
Article History
Accepted: 9 April 2024
First Online: 19 April 2024
Declarations
:
: The authors declare no competing interests.